A Randomized Neuroimaging Trial of Psilocybin in... — Clinical Trial Details

Participants

Ages

18 – 64

Sexes

Male & Female

BMI

Psychosis History

Excluded

Inclusion Criteria

Inclusion Criteria:
Able and voluntarily willing to provide written informed consent at the screening visit.
Over 18 and under 65 years old
Able to attend all study visits and complete all required assessment tools without assistance or alteration
Have a responsible individual/caregiver who is able to monitor the participant at home for 24 hours after each treatment visit
Must have a psychiatrist and/or general practitioner who is able to provide psychiatric follow-up care
Mini International Neuropsychiatric Interview (MINI)-confirmed diagnosis of depressive disorder, recurrent or single episode, without psychotic features where the duration of the current episode is at least 3 months
Depression of at least moderate severity as defined by a Hamilton Depression Rating Scale (HAMD-17) score >17

Exclusion Criteria

Exclusion Criteria:
Uncontrolled or insulin-dependent diabetes
Women who are pregnant (self-report or via urine test), nursing, or planning a pregnancy during the timespan of the study
History of seizure disorder except for seizures from electroconvulsive therapy and/or febrile seizures in childhood
History of stroke, recent myocardial infarction (< 1 year from signing of ICF), uncontrolled hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF
Abnormal and clinically significant results on a physical examination performed within one month of study participation by a general practitioner, vital signs, ECG, or laboratory test at screening
QTc prolongation on ECG defined by > 450 ms in males and > 460 ms in females in V5 on a 12-lead ECG
Positive urine drug screen for illicit drugs or drugs of abuse at screening, a week prior to treatment, and during the trial (any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion)
Serial blood counts to achieve a value to meet eligibility -- abnormalities in screening/baseline blood work (complete blood counts, electrolyte panel, etc.) will be reviewed by MD, then repeated serially until abnormalities resolve
Any symptoms consistent with psychosis
Any symptoms consistent with hypomania and/or mania as assessed by a psychiatrist
Other personal circumstances or behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin
Current or past history of bipolar I/II disorder, schizophrenia, schizoaffective disorder, psychotic disorder, or delusional disorder as assessed by a structured clinical interview (MINI)
≥ 1 suicide attempt in the past year requiring hospitalization, defined using the Columbia Suicide Severity Rating Scale (CSSRS) (Q6 (past year) = "y") and clinical interview with a psychiatrist
History of substance use and/or alcohol use disorder, of moderate severity or greater, in the past 12 months
Lifetime history of substance use disorder with a hallucinogen
Lifetime history of substance-induced psychosis
Depression secondary to other medical conditions or bipolar I and II disorder
Family history of a first degree relative with a diagnosis of schizophrenia or a primary psychotic disorder and/or bipolar disorder
Exposure to psilocybin or any other psychedelic in the past 12 months prior to screening and/or during the current MDE and use of psychedelics, such as ayahuasca/LSD, during the current depressive episode
A clinical diagnosis of antisocial personality disorder and/or paranoid personality disorder (defined as meeting DSM-5.0 criteria) based on clinical interview and the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at a clinical interview by a psychiatrist
An active clinical diagnosis of borderline personality disorder as confirmed by the MINI 7.0
Diagnosis of any mild or major neurocognitive disorder meeting DSM-5 criteria and based on clinical interview/cognitive screening by a psychiatrist
Current enrolment in an interventional study for depression or participation in such within 30 days of screening
Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study

Company

Product

Legal

A Randomized Neuroimaging Trial of Psilocybin in Depression

Detailed Description

Study Protocol

Preparation

Dosing

Locations

Integration

Therapeutic Protocol

Study Arms & Interventions

Psilocybin–Psilocybin

Interventions

MCC–Psilocybin (Delayed start)

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators